Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 496.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 174,061 shares of the company's stock after buying an additional 144,883 shares during the quarter. Barclays PLC owned 0.33% of Janux Therapeutics worth $7,907,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in Janux Therapeutics by 0.6% in the third quarter. FMR LLC now owns 7,824,675 shares of the company's stock worth $355,475,000 after acquiring an additional 47,075 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company's stock valued at $114,587,000 after purchasing an additional 721,563 shares during the last quarter. Logos Global Management LP boosted its stake in Janux Therapeutics by 400.0% in the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company's stock worth $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in Janux Therapeutics by 190.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company's stock worth $17,985,000 after purchasing an additional 259,445 shares in the last quarter. Finally, Samlyn Capital LLC grew its position in Janux Therapeutics by 9.6% during the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company's stock worth $13,602,000 after purchasing an additional 28,312 shares during the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

NASDAQ:JANX traded down $4.48 during trading hours on Wednesday, reaching $55.13. The company had a trading volume of 805,748 shares, compared to its average volume of 786,253. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $71.71. The business's 50 day moving average price is $53.37 and its 200-day moving average price is $46.92. The firm has a market cap of $2.89 billion, a PE ratio of -47.12 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analysts' expectations of $1.50 million. Janux Therapeutics's revenue was down 82.6% compared to the same quarter last year. On average, analysts expect that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on JANX shares. Stifel Nicolaus raised their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Janux Therapeutics in a research note on Wednesday, December 11th. UBS Group began coverage on Janux Therapeutics in a research note on Thursday, October 24th. They set a "buy" rating and a $69.00 price target on the stock. HC Wainwright increased their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. Finally, Leerink Partners lifted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Janux Therapeutics has an average rating of "Buy" and an average target price of $89.90.

Insider Activity

In other news, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00. Following the sale, the chief executive officer now owns 242,054 shares in the company, valued at $16,217,618. This trade represents a 5.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ra Capital Management, L.P. bought 1,200,000 shares of the business's stock in a transaction dated Friday, October 18th. The shares were bought at an average cost of $44.75 per share, with a total value of $53,700,000.00. Following the purchase, the director now directly owns 9,317,246 shares of the company's stock, valued at approximately $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 192,032 shares of company stock worth $9,512,515 in the last ninety days. Company insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.